Trial reportBMC medicine2026
Effect of Vitamin C on bleeding and pain after kidney biopsy: a randomized controlled trial.
Trial report in BMC medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
backgroundPercutaneous renal biopsy (PRB) is an essential diagnostic procedure for kidney diseases, yet postbiopsy perirenal hematoma and pain remain frequent complications. Vitamin C has emerging evidence supporting its role in reducing perioperative bleeding and pain, but its efficacy in the context of PRB is unknown.
methodsThis single-center, prospective, open-label, randomized controlled trial enrolled 710 adults with chronic kidney disease (CKD) scheduled for an ultrasound-guided native kidney biopsy. Participants were randomly assigned (1:1) to receive perioperative intravenous vitamin C (20 mg/kg at 6 h before and 18 h after biopsy) or standard care alone. The primary outcomes were the area of perirenal hematoma on renal ultrasound at 24 h and self-reported pain intensity (Visual Analogue Scale, VAS) at 2, 12, and 24 h post-biopsy.
resultsAll 710 randomized participants were included in the analysis. The adjusted mean difference in hematoma area at 24 h was 4.44 mm² (95% CI, -52.31 to 61.18; P = 0.878). After multiple testing correction, there were no significant differences in the primary pain outcome (VAS scores) between groups at any time point; however, an exploratory analysis of pain severity categories indicated a less favorable distribution in the Vitamin C group at 12 h (P for trend =0.033). The incidence of any perirenal hematoma was 56.3% in the vitamin C group versus 50.1% in the control group (risk ratio, 1.12; 95% CI, 0.98-1.29; P = 0.098). Rates of other bleeding complications and adverse events were low and comparable between groups.
conclusionsIn CKD patients undergoing PRB, perioperative intravenous vitamin C did not reduce the size of perirenal hematoma, alleviate postbiopsy pain, or decrease the incidence of bleeding complications within 24 h. These findings do not support the routine use of vitamin C for preventing complications after kidney biopsy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.